Table 2.
Summary of PTLD cases received CD19 CAR-T therapy.
| Patient | Age | Sex | SOT, years | Time of PTLD diagnosis | EBV tumor status | Pathology | Therapy before CAR-T | Immunosuppressive therapy in CAR-T | CRS | ICANS | Outcome | Maintenance therapy after CAR-T | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | 54 | M | Kidney, Pancreas |
20 years | Negative | DLBCL | RIS, Rituximan, R-CHOP, R-ICE |
None | Grade 1 | Grade 2 | SD, death at day 115 | None | (39) |
| Patient 2 | 54 | F | Heart | 27 years | Negative | DLBCL | RIS, R-CHOP, R-ICE |
Lower dose of Sirolimus | Grade 2 | Grade 3 | PD, death at day 44 | None | (39) |
| Patient 3 | 71 | M | Kidney | 10 years | Negative | DLBCL | RIS, R-CHOP, R-DHAX, Ibrutinib |
Lower dose of Prednisone | Grade 2 | Grade 4 | PD, Death at day 15 | None | (39) |
| Patient 4 | 38 | M | Kidney | 10 years | Negative | DLBCL | RIS, R-CHOP, R-GEM-Ox |
Prednisone (5 mg/day) |
Grade 1 | None | CR, Lasts up to +28 weeks | None | (40) |
| Patient 5 | 44 | M | Kidney | 10 years | Negative | DLBCL | RIS, R-CHOP | None | Grade 1 | Grade 3 | CR, Refractory at +34 weeks. | None | (40) |
| Patient 6 | 41 | M | Kidney | 7 years | Negative | DLBCL | R-EPOCH, R-GDP, R-ESHAP, Pola+BR |
None | None | None | PR, PD at +12 weeks | None | (40) |
| Patient 7 | 69 | M | Kidney | 25 years | Negative | DLBCL | R-POCH, R-GDP | Lower dose of Tacrolimus | Grade 1 | None | CR, Refractory at 3 months | None | (41) |
| Patient 8 | 50 | F | Kidney | 5 years | Negative | DLBCL | R-CHOP, R-ICE, ASCT |
Lower dose of Tacrolimus | Grade 2 | None | CR, Lasts up to 9 months | None | (41) |
| Patient 9 | 66 | M | Liver | 8 years | Negative | DLBCL | R-HOP, ICE | Lower dose of Tacrolimus | Grade 1 | None | PR, Lasts up to 3 months | None | (41) |
| Patient 10 | 4 | M | Liver | 21 months | Positive | BL-PTLD | R+CTX+ Methylprednis |
None | Grade 2 | None | CR, Lasts up to 16 months | None | (42) |
| Patient 11 | 17 | F | Heart | 4 months | Positive | DLBCL | RIS, R-COP, R-COPADM, R-CYVE, O-ICE |
Lower dose of Tacrolimus and Prednisone | Grade 1 | none | CR, Lasts up to 6 months. | Plan to undergo HCT | (43) |
PTLD, posttransplant lymphoproliferative disorders; DLBCL, diffuse large B cell lymphoma; EBV, Epstein Barr virus; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; RIS, reduction in immunosuppression; R, rituximab; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisone; DHAX, dexamethasone, cytarabine, and oxaliplatin; ICE, ifosfamide, carboplatin, and etoposide; EPOCH, etoposide, adriamycin, vincristine, cyclophosphamide, prednisone; GDP, gemcitabine, cisplatin, dexamethasone; ESHAP, etoposide, methylprednisolone, cisplatin, cytarabine; Pola+BR, polatuzumab vedotin, bendamustine, rituximab; COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin, and high dose methotrexate; O-ICE, obinutuzumab-ICE; CYVE, cytarabine, etoposide; ASCT, autologous stem cell transplantation; HCT, hematopoietic cell transplantation.